References
- Frantzi M, Latosinska A, Fluhe L, et al. Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat Rev Urol. 2015;12(6):317–330.
- Kim JJ. Recent advances in treatment of advanced urothelial carcinoma. Curr Urol Rep. 2012;13(2):147–152.
- Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–4461.
- McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15(5):1853–1857.
- Bukhari N, Al-Shamsi HO, Azam F. Update on the treatment of metastatic urothelial carcinoma. Sci World J. 2018;2018:1–7.
- Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026.
- Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30(6):970–976.
- Powles T, Duran I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–757.
- National Institute for Health and Care Excellence (NICE). TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy 2018. [cited 12 March 2019]. Available from: https://www.nice.org.uk/guidance/ta519/chapter/1-Recommendations
- Australian Government Department of Health. Positive recommendations July 2018. 2018 [cited 2019 Apr 15]. Available from: http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2018-07/positive-recommendations-07-2018.pdf
- Canadian Agency for Drugs and Technologies in Health. Keytruda for Metastatic Urothelial Carcinoma – Details 2018. [cited 2019 Apr 15]. Available from: https://www.cadth.ca/keytruda-metastatic-urothelial-carcinoma-details
- Srivastava T, Prabhu V, Li H, et al. Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in Sweden. Eur Urol Oncol. 2018. DOI:10.1016/j.euo.2018.09.012
- Sarfaty M, Hall PS, Chan KKW, et al. Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer. Eur Urol. 2018;74(1):57–62.
- Criss SD, Weaver DT, Sheehan DF, et al. Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States. Urol Oncol. 2019;37(3):180.e11–180.e18.
- Gelb D, Zhong Y, Perini R, et al. [P786] Network meta-analysis (NMA) and matching-adjusted indirect comparison (MAIC) of pembrolizumab (pembro) versus atezolizumab (atezo) for second-line (2L) locally advanced/metastatic urothelial carcinoma (mUC). National Harbour (MA): Society of Immunotherapy of Cancer; 2019.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer V.3.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed January 17, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Latimer NR, Abrams KR, Lambert PC, et al. Adjusting for treatment switching in randomised controlled trials – a simulation study and a simplified two-stage method. Stat Methods Med Res. 2017;26(2):724–751.
- Kamat AM, Cao Z, He J, et al. Costs of care for patients receiving chemotherapy for advanced bladder cancer. J Clin Pathways. 2017;3(10):63–70.
- Choueiri TK, Ross RW, Jacobus S, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. JCO. 2012;30(5):507–512.
- Petrylak DP, Tagawa ST, Kohli M, et al. Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: an open-label, three-arm, randomized controlled phase II trial. J Clin Oncol. 2016;34(13):1500–1509.
- National Institute for Health and Care Excellence (NICE). TA525: atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy 2018. [cited 2020 Feb 4]. Available from: https://www.nice.org.uk/guidance/ta492/
- Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012 ;12:9.
- Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43(3):203–220.
- Hatswell AJ, Pennington B, Pericleous L, et al. Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health Qual Life Outcomes. 2014;12:140.
- DMD America. AnalySource Suite of Drug Pricing Services. 2018. [cited 2019 Jan]. Available from: https://www.analysource.com/about.html
- Centers for Medicare & Medicaid Services. Physician Fee Schedule Search 2018. [cited 2018 May 10]. Available from: https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx
- Centers for Medicare & Medicaid Services. ASP Drug Pricing Files 2018. [cited 2018 May 10]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2018ASPFiles.html
- Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project [cited 2018 May 10]. Available from: https://hcupnet.ahrq.gov/#setup
- Zhong Y, Li H, He J, et al. C17 Pattern of disease management costs for advanced bladder cancer patients receiving chemotherapy. AMCP Managed Care & Speciality Pharamacy Annual Meeting; 2019; San Diego, CA.
- US Food and Drugs Administrations. KEYTRUDA® (pembrolizumab) injection, for intravenous use Initial U.S. Approval: 2014. [2014; cited 2019 Apr 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s034lbl.pdf.
- US Food and Drugs Administrations. TECENTRIQ® (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2016. [2018; 2019 Mar 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761034s010lbl.pdf
- US Food and Drugs Administrations. TAXOL® (paclitaxel) INJECTION 2019 [cited 2019 May 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf
- US Food and Drugs Administrations. Docetaxel Injection 2012. [cited 2019 May 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201525s002lbl.pdf
- National Cancer Institute. SEER Cancer Stat Facts: Bladder Cancer [cited 2018 May 10]. Available from: https://seer.cancer.gov/statfacts/html/urinb.html
- Nishijima TF, Shachar SS, Nyrop KA, et al. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist. 2017;22(4):470–479.